checkAd
    Startseite > Aktien > Ocuphire Pharma > Nachrichten
    Ocuphire Pharma Aktie
    1,7900
     
    USD
    +9,15 %
    +0,1500 USD
    Letzter Kurs 16:42:38 Nasdaq
    1,7800
     
    USD
    100 STK
    Geldkurs 16:42:38
    1,8300
     
    USD
    100 STK
    Briefkurs 16:42:38
    ISIN: US67577R1023 · WKN: A2QG4Z · SYM: OCUP · USA

    Neueste Nachrichten

    Ocuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual Meeting
    22.04.24 · globenewswire · Ocuphire Pharma
    First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery
    11.04.24 · globenewswire · Ocuphire Pharma
    Ocuphire Announces the U.S. Commercial Launch of RYZUMVl (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris
    01.04.24 · globenewswire · Ocuphire Pharma
    Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Update
    08.03.24 · globenewswire · Ocuphire Pharma
    Ocuphire Pharma to Present in the BIO CEO & Investor Conference
    23.02.24 · globenewswire · Ocuphire Pharma
    Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    15.02.24 · globenewswire · Ocuphire Pharma
    Ocuphire Pharma Strengthens Leadership Team with Key Appointments
    14.02.24 · globenewswire · Ocuphire Pharma
    Ocuphire Pharma Announces Presentation on APX3330 at the Annual Angiogenesis, Exudation, and Degeneration 2024 Conference
    05.02.24 · globenewswire · Ocuphire Pharma
    Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    24.01.24 · globenewswire · Ocuphire Pharma
    Ocuphire Pharma Receives FDA Agreement Under Special Protocol Assessment for LYNX-2 Phase 3 Trial of Phentolamine Ophthalmic Solution for the Treatment of Decreased Visual Acuity under Dim (mesopic) Light Conditions
    04.01.24 · globenewswire · Ocuphire Pharma
    Ocuphire Pharma Announces Presentation at Ophthalmology Innovation Summit (OIS) XIII
    30.11.23 · globenewswire · Ocuphire Pharma
    Ocuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    27.11.23 · globenewswire · Ocuphire Pharma